ICM Asset Management’s ENDRA Life Sciences NDRA Stock Holding History

ICM Asset Management’s Portfolio NDRA Stock Details NDRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$300K	Buy	12 +1	+9%	+$30.8K	1.65%	21
2020 Q2	$387K	Sell	11 -14	-56%	-$406K	2.04%	20
2020 Q1	$633K	Buy	25 +6	+32%	+$278K	0.62%	21
2019 Q4	$1.11M	Sell	19 -1	-5%	-$37.2K	0.92%	27
2019 Q3	$729K	Hold	20	–	–	0.56%	29
2019 Q2	$1.19M	Buy	20 +1	+5%	+$50.5K	0.88%	29
2019 Q1	$1.12M	Hold	19	–	–	0.86%	27
2018 Q4	$1.01M	Buy	19 +15	+375%	+$1.74M	0.89%	25
2018 Q3	$400K	Buy	+4	New	+$360K	0.28%	45

Other funds holding NDRA

KJHP

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

GIA

Gladstone Institutional Advisory Palm Beach Gardens, Florida $2.7B AUM 23.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ICM Asset Management's NDRA Position: Q3 2020 in Review

ICM Asset Management increased its ENDRA Life Sciences (NDRA) stake by 9.1% in Q3 2020, buying an estimated $30.8K and bringing the position to 12 shares worth $300K. The position accounts for 1.65% of the portfolio, ranked #21.

ICM Asset Management first reported a position in NDRA in Q3 2018 and has held it in 9 quarters since. The position peaked at $1.19M in Q2 2019. 9 funds tracked by Wall St. Rank hold NDRA as of Q3 2020.

ICM Asset Management held 12 shares of ENDRA Life Sciences worth $300K as of Q3 2020.
ICM Asset Management bought 1 ENDRA Life Sciences share in Q3 2020, an estimated $30.8K.
ENDRA Life Sciences made up 1.65% of ICM Asset Management's portfolio in Q3 2020, its #21 holding.
ICM Asset Management first reported a position in ENDRA Life Sciences in Q3 2018 and has held it in 9 quarters since.
ICM Asset Management's ENDRA Life Sciences position peaked at $1.19M in Q2 2019.
9 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q3 2020.

Based on ICM Asset Management's 13F filing for Q3 2020, filed 22 Oct 2020.